Eric D. Whitman

5.0k total citations
71 papers, 2.1k citations indexed

About

Eric D. Whitman is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Eric D. Whitman has authored 71 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 22 papers in Immunology and 16 papers in Molecular Biology. Recurrent topics in Eric D. Whitman's work include CAR-T cell therapy research (32 papers), Immunotherapy and Immune Responses (18 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Eric D. Whitman is often cited by papers focused on CAR-T cell therapy research (32 papers), Immunotherapy and Immune Responses (18 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Eric D. Whitman collaborates with scholars based in United States, United Kingdom and Germany. Eric D. Whitman's co-authors include René González, John Nemunaitis, John A. Glaspy, Thomas Amatruda, Gregory A. Daniels, Kevin J. Harrington, Neil Senzer, Howard L. Kaufman, Tony Reid and Jacob C. Langer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eric D. Whitman

67 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric D. Whitman United States 23 1.1k 798 696 507 259 71 2.1k
Nicolas Mach Switzerland 25 1.2k 1.0× 1.6k 2.0× 553 0.8× 213 0.4× 297 1.1× 96 3.1k
James N. Lowder United States 23 571 0.5× 703 0.9× 565 0.8× 305 0.6× 103 0.4× 57 2.1k
Carsten Ziske Germany 22 929 0.8× 371 0.5× 267 0.4× 176 0.3× 186 0.7× 52 1.6k
Marc K. Wallack United States 23 829 0.7× 592 0.7× 373 0.5× 271 0.5× 90 0.3× 109 2.0k
René Lafrenière Canada 20 1.5k 1.3× 1.8k 2.3× 457 0.7× 387 0.8× 67 0.3× 80 3.0k
Alexander Fefer United States 32 1.4k 1.3× 1.6k 2.0× 382 0.5× 442 0.9× 148 0.6× 81 4.7k
Michael Linenberger United States 24 396 0.4× 756 0.9× 646 0.9× 277 0.5× 78 0.3× 70 3.0k
Lukas Flatz Switzerland 29 1.8k 1.7× 1.6k 2.0× 721 1.0× 177 0.3× 762 2.9× 102 4.0k
Bernd Gruhn Germany 38 976 0.9× 788 1.0× 1.1k 1.5× 316 0.6× 279 1.1× 138 3.9k
Denis Guyotat France 31 1.0k 0.9× 553 0.7× 956 1.4× 126 0.2× 293 1.1× 124 3.4k

Countries citing papers authored by Eric D. Whitman

Since Specialization
Citations

This map shows the geographic impact of Eric D. Whitman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric D. Whitman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric D. Whitman more than expected).

Fields of papers citing papers by Eric D. Whitman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric D. Whitman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric D. Whitman. The network helps show where Eric D. Whitman may publish in the future.

Co-authorship network of co-authors of Eric D. Whitman

This figure shows the co-authorship network connecting the top 25 collaborators of Eric D. Whitman. A scholar is included among the top collaborators of Eric D. Whitman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric D. Whitman. Eric D. Whitman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kluger, Harriet M., Götz Ulrich Grigoleit, Sajeve Thomas, et al.. (2025). Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Communications. 45(10). 1229–1234. 3 indexed citations
2.
3.
Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immuno-Oncology Technology. 20. 100591–100591. 7 indexed citations
4.
5.
Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study. SHILAP Revista de lepidopterología. A873–A873. 5 indexed citations
6.
Ferretti, Andrew, Tomasz Kula, Yifan Wang, et al.. (2020). Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity. 53(5). 1095–1107.e3. 182 indexed citations
7.
Hodi, F. Stephen, Dmitry I. Gabrilovich, Melanie Chin, et al.. (2017). A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma. Annals of Oncology. 28. xi30–xi30. 5 indexed citations
8.
Hallmeyer, Sigrun, René González, David H. Lawson, et al.. (2017). Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Research. 27(6). 585–590. 20 indexed citations
9.
Hughes, Marybeth S., Jonathan S. Zager, Mark B. Faries, et al.. (2015). Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. Annals of Surgical Oncology. 23(4). 1309–1319. 101 indexed citations
10.
Koshenkov, Vadim P., et al.. (2012). Role of sentinel lymphadenectomy in thin cutaneous melanomas with positive deep margins on initial biopsy. Journal of Surgical Oncology. 106(4). 363–368. 15 indexed citations
11.
Bedikian, Agop Y., et al.. (2010). A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Research. 20(3). 218–226. 66 indexed citations
12.
Richards, Jon, A. Y. Bedikian, René González, et al.. (2005). High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial. Journal of Clinical Oncology. 23(16_suppl). 7543–7543. 5 indexed citations
13.
Whitman, Eric D.. (2003). Surgical margins in melanoma. Facial Plastic Surgery Clinics of North America. 11(1). 87–91.
14.
Brunt, L. Michael, Jacob C. Langer, Mary Quasebarth, & Eric D. Whitman. (1996). Comparative analysis of laparoscopic versus open splenectomy. The American Journal of Surgery. 172(5). 596–601. 140 indexed citations
15.
Whitman, Eric D.. (1996). Complications associated with the use of central venous access devices. Current Problems in Surgery. 33(4). 309–378. 49 indexed citations
16.
Whitman, Eric D., Mark E. Frisse, & Michael G. Kahn. (1995). The Impact of Data Sharing on Data Quality. PubMed Central. 952–952. 1 indexed citations
17.
Horne, McDonald K., et al.. (1995). Venographic surveillance of tunneled venous access devices in adult oncology patients. Annals of Surgical Oncology. 2(2). 174–178. 44 indexed citations
18.
Whitman, Eric D., et al.. (1995). Comparison of diagnostic specimens and methods to evaluate infected venous access ports. The American Journal of Surgery. 170(6). 665–670. 26 indexed citations
19.
Tsung, Kangla, et al.. (1995). Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1β. Annals of Surgical Oncology. 2(2). 151–159. 18 indexed citations
20.
Davis, Ronald M., Eric D. Whitman, Walter A. Orenstein, et al.. (1987). A PERSISTENT OUTBREAK OF MEASLES DESPITE APPROPRIATE PREVENTION AND CONTROL MEASURES. American Journal of Epidemiology. 126(3). 438–449. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Mach Breakdown of academic impact, for papers by James N. Lowder Breakdown of academic impact, for papers by Carsten Ziske Breakdown of academic impact, for papers by Marc K. Wallack Breakdown of academic impact, for papers by René Lafrenière Breakdown of academic impact, for papers by Alexander Fefer Breakdown of academic impact, for papers by Michael Linenberger Breakdown of academic impact, for papers by Lukas Flatz Breakdown of academic impact, for papers by Bernd Gruhn Breakdown of academic impact, for papers by Denis Guyotat
Rankless by CCL
2026